Clinical trial
SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00026260 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00026260 |
|---|---|
| Title | SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer |
| Official title | A Phase II Evaluation of SU5416 (NSC 696819) in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | semaxanib |
| Completion | Oct 1, 2003 |
| First posted | Oct 21, 2003 |
| Last update posted | Jun 24, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: